Nicholas Lavin
Child & Adolescent Psychiatry · Lafayette, LANPI 1417214164
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 381 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 29.0% of the total. Among child & adolescent psychiatry clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 381 payments — averaging $14.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Supernus Pharmaceuticals, Inc.$862
- Corium, LLC$628
- Johnson & Johnson$615
- Tris Pharma Inc$453
- Ironshore Pharmaceuticals Inc.$303
- plus $1K from 11 others
What the payments were for
- Food & beverage$5,613100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 135 | $1,628 |
| Supernus Pharmaceuticals, Inc. | 47 | $862 |
| Corium, LLC | 46 | $628 |
| Johnson & Johnson | 39 | $615 |
| Tris Pharma Inc | 27 | $453 |
| Ironshore Pharmaceuticals Inc. | 21 | $303 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $301 |
| Adlon Therapeutics L.p. | 14 | $219 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $154 |
| Noven Therapeutics, LLC | 7 | $128 |
| Neos Therapeutics, LP | 6 | $103 |
| Bausch Health US, LLC | 4 | $75 |
| Idorsia Pharmaceuticals US Inc | 3 | $49 |
| Eisai Inc. | 3 | $48 |
| Vertical Pharmaceuticals, LLC | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$161
How this compares
$5,621 in reported general payments places this provider in the 95th percentile of 70 child & adolescent psychiatry providers in Louisiana.
See all child & adolescent psychiatry providers in Louisiana →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 11 | $82 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Lafayette
- Ching-Shih HuLafayette$3K
- Ashley AlbaradoLafayette$86
- Manish SaranShreveport$11K
- Jason WuttkeNew Orleans$11K
- Mark SandsMetairie$5K
- Swathi ParvataneniShreveport$4K
- Adewale OyemadeNew Orleans$4K
- Sadaf JavaidShreveport$4K
- Brandi GilmoreRaceland$3K
- Katherine SmithShreveport$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.